Get the Stockscreener App
49.23
0.26%
-0.13
After Hours:
49.50
0.27
+0.55%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $49.23, with a volume of 14.24M.
It is down -0.26% in the last 24 hours and down -17.94% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$49.36
Open:
$49.18
24h Volume:
14.24M
Relative Volume:
1.18
Market Cap:
$104.46B
Revenue:
$48.30B
Net Income/Loss:
$-8.95B
P/E Ratio:
-11.14
EPS:
-4.42
Net Cash Flow:
$13.94B
1W Performance:
-2.44%
1M Performance:
-17.94%
6M Performance:
-7.43%
1Y Performance:
+2.91%
1-Day Range:
$49.06
$50.09
1-Week Range:
$44.93
$51.60
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
49.23 | 104.46B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics - MSN
Bristol Myers (BMY) Gains FDA Nod for Updated Camzyos Label to Simplify Treatment | BMY Stock News - GuruFocus
Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures - TipRanks
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Bristol Myers (BMY) Target Price Trimmed as Revenue Projections Dip | BMY Stock News - GuruFocus
Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now? - Insider Monkey
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Gilead Vs Bristol Myers: Which Biotech Bigwig Is A Better Bet Now? - Barchart.com
Bristol-Myers Squibb (BMY): Potential 19.73% Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Ca - GuruFocus
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Cancer Diagnosis - GuruFocus
Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Bristol Myers stumbles in bid to widen heart drug’s use - BioPharma Dive
BMO maintains Bristol-Myers $61 target after trial setback By Investing.com - Investing.com India
Bristol-Myers stock dips on trial results - Investing.com Australia
BMS’ Camzyos fails to show new cardiomyopathy benefit in Phase III - PharmaLive
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - 01net
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis - Quantisnow
Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? - Insider Monkey
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BMS Phase III Camzyos trial misses endpoints - The Pharma Letter
Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects - TipRanks
Chemotherapy Market Overall Study Report 2025-2032 | - openPR.com
Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos - GuruFocus
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bristol Myers falls as heart disease drug fails in late-stage trial - TradingView
Bristol Myers reports setback in Camzyos heart drug trial - Investing.com
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsight - The Globe and Mail
BMS’ Opdivo combo approved in US for hepatocellular carcinoma - Yahoo Finance
Bristol Myers: new approval for Opdivo+Yervoy - MarketScreener
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week - MedCity News
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit - Medical Dialogues
Bristol Myers Squibb (BMY) Secures FDA Approval for Liver Cancer Treatment - GuruFocus
UBS cuts Bristol-Myers Squibb price target to $54 from $60 By Investing.com - Investing.com South Africa
Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods - insights.citeline.com
Bristol-Myers Squibb Faces Q1 Expectations With Eliquis And Revlimid Leading - Finimize
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? - Insider Monkey
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer - Fierce Pharma
UBS cuts Bristol-Myers Squibb price target to $54 from $60 - Investing.com Australia
Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report - TradingView
Here's What To Expect From Bristol-Myers Squibb's Next Earnings Report - Barchart.com
Dasatinib Drugs Market Deep Research 2025-2032 | Bristol-Myers - openPR.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
10 Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bristol Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises - MarketScreener
FDA Approves Opdivo (BMY) Plus Yervoy Combo for Colorectal Cance - GuruFocus
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):